Technical Data
C7850-28
C9 Terminal Complement Complex (TCC, MAC complex) (FITC)
Description:
The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 molecules associate with the C5b678 complex, which is also termed the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components. C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.

Applications:
Suitable for use in Flow Cytometry, ELISA, Functional Studies, Immunofluorescence and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry: Frozen
Immunohistochemistry: Paraffin
Flow Cytometry: 1:50
Optimal dilutions to be determined by the researcher.

Positive Control: Mucosa from patients with H. Pylori.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20°C. Aliquots are stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. FITC conjugates are sensitive to light.
TypeIsotypeCloneGrade
MabIgG2a13A37Affinity Purified
SizeStorageShippingSourceHost
100ug-20°CBlue IceHumanMouse
Concentration:
~0.1mg/ml
Immunogen:
Purified MAC
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in PBS, 0.1% BSA, 0.02% sodium azide. Labeled with fluorescein isothiocyanate (FITC).
Specificity:
Recognizes a C9 neoantigen of the human TCC. Species Crossreactivity: equine and porcine.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Mollnes, T et al; Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985, 22: 197. 2. Mollnes, T et al; Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 1985, 22:183. 3. Pettersen, H et al; Human alveolar macrophages synthesize active complement components C6, C7, and C8 in vitro. Scand J Immunol 1987, 25: 567. 4. Berstad, A et al ; Epithelium related deposition of activated complement in Helicobacter pylori associated gastritis. Gut 1997, 40:196. 5. Stewart, M et al. Antiphospholipid antibody-dependent C5b-9 formation. BJH 1997, 96:451. 6. Meuwissen, M et al. Colocalisation of intraplauq C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Path 2005, 59:126.